Overcoming Drug Resistance in Mantle Cell Lymphoma Using a Combination of Dose-Dense and Intense Therapy

REFERENCES

• Velders, G.A.; Kluin-Nelemans, J.C.; De Boer, C.J.; Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996, 14, 1269–1274.
   PubMed Web of Science ®Google Scholar
• Harris, N.; Jaffe, E.; Stein, H.; A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84, 1361–1392.
   PubMed Web of Science ®Google Scholar
• Weisenburger, D.D.; Armitage, J.O. Mantle cell lymphoma: an entity comes of age. Blood 1996, 87, 4483–4494.
   PubMed Web of Science ®Google Scholar
• Li, J.Y.; Gaillard, F.; Moreau, A.; Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999, 154, 1449–1452.
   PubMed Web of Science ®Google Scholar
• Teodorovic, I.; Pittaluga, S.; Kluin-Nelemans, J.C.; Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995, 13, 2819–2826.
   PubMed Web of Science ®Google Scholar
• Samaha, H.; Dumontet, C.; Ketterer, N.; Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998, 12, 1281–1287.
   PubMed Web of Science ®Google Scholar
• Hiddemann, W.; Unterhalt, M.; Herrmann, R.; Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998, 16, 1922–1930.
   PubMed Web of Science ®Google Scholar
• Norton, A.J.; Matthews, J.; Pappa, V.; Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995, 6, 249–256.
   PubMed Web of Science ®Google Scholar
• Khouri, I.F.; Saliba, R.M.; Okoroji, G.L.; Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission. Cancer 2003, 98, 2630–2635.
   PubMed Web of Science ®Google Scholar
• Zucca, E.; Roggero, E.; Pinotti, G.; Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6, 257–262.
   PubMed Web of Science ®Google Scholar
• Vandenberghe, E.; Ruiz de Elvira, C.; Loberiza, F.R.; Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120, 793–800.
   PubMed Web of Science ®Google Scholar
• Wang, M.; Fayad, L.; Cabanillas, F.; Hagemeister, F.; McLaughlin, P.; Rodriguez, M.A.; Kwak, L.W.; Zhou, Y.; Kantarjian, H.; Romaguera, J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 2008, 113, 2734–2741.
   PubMed Web of Science ®Google Scholar
• Ribrag, V.; Koscielny, S.; Carpiuc, I.; Cebotaru, C.; Vande Walle, H.; Talbot, M.; Fenaux, P.; Bosq, J. Prognostic value of GST-pi expression in diffuse large B-cell lymphomas. Leukemia 2003, 17, 972–977.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Cancer Therapy Evaluation Program. Hematological toxicities. In Common Terminology Criteria for Adverse Events, Version 3.0. Washington, DC: DCTD, NCI, NIH, and DHHS, 2003, Available from URL: http;//ctep.cancer.gov.
   Google Scholar
• Cheson, B.D.; Horning, S.J.; Coiffier, B.; Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17, 1244–1253.
   PubMed Web of Science ®Google Scholar
• Sherratt, P.J.; Pulford, D.J.; Harrison, D.J.; Green, T.; Hayes, J.D. Evidence that human class Theta glutathione S-transferase T1–1 can catalyse the activation of dichloromethane, a liver and lung carcinogen in the mouse. Comparison of the tissue distribution of GST T1–1 with that of classes Alpha, Mu and Pi GST in human. Biochem J 1997, 15, 837–846.
   Google Scholar
• Hohaus, S.; Massini, G.; D’Alo’, F.; Guidi, F.; Putzulu, R.; Scardocci, A.; Rabi, A.; Di Febo, A.L.; Voso, M.T.; Leone, G. Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis. Clin Cancer Res 2003, 9, 3435–3440.
   PubMed Web of Science ®Google Scholar
• Bennaceur-Griscelli, A.; Bosq, J.; Koscielny, S.; Lefrere, F.; Turhan, A.; Brousse, N.; Hermine, O.; Ribrag, V. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 2004, 10, 3029–3034.
   PubMed Web of Science ®Google Scholar
• Thieblemont, C.; Nasser, V.; Felman, P.; Leroy, K.; Gazzo, S.; Callet-Bauchu, E.; Loriod, B.; Granjeaud, S.; Gaulard, P.; Haioun, C.; Traverse-Glehen, A.; Baseggio, L.; Bertucci, F.; Birnbaum, D.; Magrangeas, F.; Minvielle, S.; Avet-Loiseau, H.; Salles, G.; Coiffier, B.; Berger, F.; Houlgatte, R. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004, 103, 2727–2737.
   PubMed Web of Science ®Google Scholar
• Hu, X.; Xia, H.; Srivastava, S.K.; Activity of four allelic forms of glutathione S-transferase P1-1 hGSTP1-1 for diol epoxides of polycyclic aromatic hydrocarbons. Biochem Biophys Res Comm 1997, 238, 397–402.
   PubMed Web of Science ®Google Scholar
• Srivastava, S.K.; Singhal, S.S.; Hu, X.; Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999, 366, 89–94.
   PubMed Web of Science ®Google Scholar
• Pandya, U.; Srivastava, S.K.; Singha, S.S.; Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem Biophys Res Commun 2000, 278, 258–262.
   PubMed Web of Science ®Google Scholar
• Ishimoto, T.M.; Ali-Osman, F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 2002, 12, 543–553.
   PubMedGoogle Scholar
• Ali-Osman, F.; Akande, O.; Antoun, G.; Molecular cloning, characterization and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase-pi gene variants. J Biol Chem 1997, 272, 10004–10012.
   PubMed Web of Science ®Google Scholar
• Weiss, M.; Maslak, P.; Feldman, E.; Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996, 14, 2480–2485.
   PubMed Web of Science ®Google Scholar
• Wang, W.S.; Tzeng, C.H.; Chiou, T.J.; High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Zhonghua Yi Xue Za Zhi (Chinese Medical Journal) (Taipei) 1996, 57, 100–105.
   PubMedGoogle Scholar
• Mathias, J.R.; Ulrich von, G.; Norbert, N.; Harald, B.; Eckhart, W.; Manfred, W.; Gerhard, H.; Christina, B.; Heinz, A.D.; Martina, S.; Dorothea, K.; Ulrich, K.; Wolfgang, K.; Wolfram, B. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the study group indolent lymphomas (StiL). Blood (ASH Annual Meeting Abstracts) 2008, 112, 2596.
   PubMedGoogle Scholar
• Goy, A.; Bernstein, S.H.; Kahl, B.S.; Djulbegovic, B.; Robertson, M.J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J.P.; Lonial, S.; Nasta, S.; O’Connor, O.A.; Shi, H.; Boral, A.L.; Fisher, R.I. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20, 520–525.
   PubMed Web of Science ®Google Scholar
• Hess, G.; Herbrecht, R.; Romaguera, J.; Verhoef, G.; Crump, M.; Gisselbrecht, C.; Laurell, A.; Offner, F.; Strahs, A.; Berkenblit, A.; Hanushevsky, O.; Clancy, J.; Hewes, B.; Moore, L.; Coiffier, B. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27, 3822–3829.
   PubMed Web of Science ®Google Scholar
• Jonathan, W.F.; Jeff, S.; Julia, S.; Patrick, B.J.; Sven De, V.; Ann, L.; John, P.L.; Larry, D.C.; Rajni, S.; Stephanie A.G.; John, S.; Julie, M.V.; Ann, M.L.; Levy, R.; Margaret, A.S. Fostamatinib disodium (FosD), an oral inhibitor of Syk, is well-tolerated and has significant clinical activity in diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (SLL/CLL). Blood (ASH Annual Meeting Abstracts). 2008, 112, 3.
   Web of Science ®Google Scholar
• Rizzieri, D.A.; Feldman, E.; Dipersio, J.F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V.M.; Albitar, M.; Bedrosian, C.L.; Giles, F.J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008, 14, 2756–2762.
   PubMed Web of Science ®Google Scholar